BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34836489)

  • 1. A classification based on tumor-stroma ratio and tumor budding for patients with muscle-invasive bladder cancer.
    Liu J; Li C; Huang K; Aldanakh A; Yang D; Wang J; Sun X; Song X
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):323-330. PubMed ID: 34836489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine Learning Quantified Tumor-Stroma Ratio Is an Independent Prognosticator in Muscle-Invasive Bladder Cancer.
    Zheng Q; Jiang Z; Ni X; Yang S; Jiao P; Wu J; Xiong L; Yuan J; Wang J; Jian J; Wang L; Yang R; Chen Z; Liu X
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of prognostic biomarkers associated with stromal cell infiltration in muscle-invasive bladder cancer by bioinformatics analyses.
    Li P; Cao J; Li J; Yao Z; Han D; Ying L; Wang Z; Tian J
    Cancer Med; 2020 Oct; 9(19):7253-7267. PubMed ID: 32786144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.
    Eckstein M; Matek C; Wagner P; Erber R; Büttner-Herold M; Wild PJ; Taubert H; Wach S; Sikic D; Wullich B; Geppert CI; Compérat EM; Lopez-Beltran A; Montironi R; Cheng L; van der Kwast T; Colecchia M; van Rhijn BWG; Amin MB; Netto GJ; Lehmann J; Stöckle M; Junker K; Hartmann A; Bertz S
    Eur Urol Oncol; 2024 Feb; 7(1):128-138. PubMed ID: 37562993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer-Stromal gene expressions show higher prognostic values than intrinsic tumor genes.
    Olah C; Hahnen C; Nagy N; Musial J; Varadi M; Nyiro G; Gyorffy B; Hadaschik B; Rawitzer J; Ting S; Sjödahl G; Hoffmann MJ; Reis H; Szarvas T
    Int J Cancer; 2022 Mar; 150(5):856-867. PubMed ID: 34536301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tumour stroma-immune interactions on survival prognosis and response to neoadjuvant chemotherapy in bladder cancer.
    Liu L; Xu L; Wu D; Zhu Y; Li X; Xu C; Chen K; Lin Y; Lao J; Cai P; Li X; Luo Y; Li X; Huang J; Lin T; Zhong W
    EBioMedicine; 2024 Jun; 104():105152. PubMed ID: 38728838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
    Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
    Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
    Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
    Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
    Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
    PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD19
    Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
    Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of tumour budding, tumour-stroma ratio and desmoplastic stromal reaction in gall bladder carcinoma.
    Goyal S; Banga P; Meena N; Chauhan G; Sakhuja P; Agarwal AK
    J Clin Pathol; 2023 May; 76(5):308-314. PubMed ID: 34853164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Xie H; Fu Q; Dai B; Ye D; Xu J
    Clin Cancer Res; 2018 Jul; 24(13):3069-3078. PubMed ID: 29514839
    [No Abstract]   [Full Text] [Related]  

  • 14. Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer?
    Eriksen AC; Andersen JB; Lindebjerg J; dePont Christensen R; Hansen TF; Kjær-Frifeldt S; Sørensen FB
    Diagn Pathol; 2018 Mar; 13(1):20. PubMed ID: 29558947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer.
    Shen C; Xu T; Sun Y; Wang L; Liang Z; Niu H; Jiao W; Wang Y
    Dis Markers; 2020; 2020():8866730. PubMed ID: 33456631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal LAG-3
    Zeng H; Zhou Q; Wang Z; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Xu L; Dai B; Guo J; Liu L; Zhu Y; Xu J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study.
    Smit MA; van Pelt GW; Terpstra V; Putter H; Tollenaar RAEM; Mesker WE; van Krieken JHJM
    Int J Colorectal Dis; 2021 Dec; 36(12):2729-2737. PubMed ID: 34533595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the tumor-stroma ratio in gallbladder cancer.
    Li H; Yuan SL; Han ZZ; Huang J; Cui L; Jiang CQ; Zhang Y
    Neoplasma; 2017; 64(4):588-593. PubMed ID: 28485165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Audenet F; Attalla K; Sfakianos JP
    Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.